CoChat

Gene therapy in Alzheimer’s disease – potential for disease modification

Open access
Nilsson, Per, Iwata, Nobuhisa, Muramatsu, Shin‐ichi, Tjernberg, Lars O., Winblad, Bengt, Saido, Takaomi C. · 2010 · Journal of Cellular and Molecular Medicine
Cited by 91

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Introduction Targets and ongoing research Potential gene therapy target candidates Down‐regulation of AD‐associated proteins by siRNA Concluding remarks Alzheimer’s disease (AD) is the major cause of dementia in the elderly, leading to memory loss and cognitive decline. The mechanism underlying onset of the disease has not been fully elucidated. However, characteristic pathological manifestations include extracellular accumulation and aggregation of the amyloid β‐peptide (Aβ) into plaques and intracellular accumulation and aggregation of hyperphosphorylated tau, forming neurofibrillary tangles. Despite extensive research worldwide, no disease modifying treatment is yet available. In this review, we focus on gene therapy as a potential treatment for AD, and summarize recent work in the field, ranging from proof‐of‐concept studies in animal models to clinical trials. The multifactorial causes of AD offer a variety of possible targets for gene therapy, including two neurotrophic growth factors, nerve growth factor and brain‐derived neurotrophic factor, Aβ‐degrading enzymes, such as neprilysin, endothelin‐converting enzyme and cathepsin B, and AD associated apolipoprotein E. This review also discusses advantages and drawbacks of various rapidly developing virus‐mediated gene delivery techniques for gene therapy. Finally, approaches aiming at down‐regulating amyloid precursor protein (APP) and β‐site APP cleaving enzyme 1 levels by means of siRNA‐mediated knockdown are briefly summarized. Overall, the prospects appear hopeful that gene therapy has the potential to be a disease modifying treatment for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2010.01038.x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 91

Metadata

Authors
Nilsson, P., Iwata, N., Muramatsu, S., Tjernberg, L. O., Winblad, B., & Saido, T. C.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2010-04
Volume
14
Issue
4
Pages
741-757
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2082185331
Cited by
91
References
37
FWCI
3.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy in Alzheimer’s disease – potential for disease modification. https://app.cochat.ai/papers/10.1111/j.1582-4934.2010.01038.x
The paper
Nilsson, P., Iwata, N., Muramatsu, S., Tjernberg, L. O., Winblad, B., & Saido, T. C. (2010). Gene therapy in Alzheimer’s disease – potential for disease modification. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2010.01038.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.